U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 74

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated **July 8, 2015,**
1. DLP Marquette General Hospital, LLC d/b/a UP Health System - Marquette	3. License number 21-05432-04 is amended in its entirety to read as follows:
2. 580 West College Avenue Marquette, MI 49855	4. Expiration date July 31, 2024
	5. Docket No. 030-18133 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 9 curies
D. Cesium-137 as permitted by 10 CFR 35.400	D. Sealed sources (Amersham Model CDC.T1; 3M Health Physics Model Series 6501 - 6503, inclusive; and Isotope Products Laboratories Model 67-6500 Series)	D. 400 millicuries
E. Iridium-192 as permitted by 10 CFR 35.400	E. Sealed sources (Best Medical International, Inc., Model 81-01)	E. 600 millicuries
F. Yttrium-90 as permitted by 10 CFR 35.1000	F. Sealed sources (SIR-Spheres (AEA Technology QSA, Inc.))	F. 1.08 curies
G. Uranium (depleted in Uranium-235)	G. Solid metal	G. 999 kilograms

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
21-05432-04

Docket or Reference Number
030-18133

Amendment No. 74

C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

D. and E. Possession and storage only until license is amended to authorize any brachytherapy procedure permitted by 10 CFR 35.400.

F. For medical use, as permitted by 10 CFR 35.1000, in a Sirtex Medical Limited brachytherapy afterloader delivery system.

G. Shielding in generators.

CONDITIONS

10. Locations of Use: 420 W. Magnetic Street, Marquette, Michigan and 580 W. College Avenue, Marquette, Michigan.

11. The Radiation Safety Officer for this license is **Kevin S. Gostenik, M.D.**

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use as indicated:

Authorized User	Material and Use
John Michael Pap, M.D.	10 CFR 35.100 and 35.200.
Raymond Wood, D.O.	10 CFR 35.200.
Christopher J. Mehall, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.1000, limited to yttrium-90 SIR-spheres in a Sirtex Medical Limited brachytherapy afterloader delivery system.
Nelson E. Gencheff, D.O.	10 CFR 35.200.
Gary M. Friesen, M.D.	10 CFR 35.200.
Michael Ouimette, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.1000, limited to yttrium-90 SIR-spheres in a Sirtex Medical Limited brachytherapy afterloader delivery system.
Kevin Scott Gostenik, M.D.	10 CFR 35.100, 35.200, and 35.300, limited to oral administration of sodium iodide I-131.

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
21-05432-04

Docket or Reference Number
030-18133

Amendment No. 74

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated February 13, 2014;

B. Letters dated February 7, 2014, April 11, 2005, May 25, 2005, August 12, 2009 (with attachments), February 23, 2010 (with attachments), May 13, 2014, June 19, 2014, July 28, 2014, December 1, 2014, **and July 8, 2015 (with attachments); and,**

C. Facsimile letter dated January 16, 2015.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JUL 27 2015

By Colleen Carol Casey
Colleen Carol Casey
Materials Licensing Branch
Region III